Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis
Intermediate End Points and Health Outcomes in rhGH-Treated Patients With CF (1)
The studies of rhGH for patients with CF provide no evidence about the impact of treatment on long-term health and survival. It is important to understand how well intermediate end points of pulmonary function and anthropometrics predict important health outcomes, such as mortality and quality of life. To evaluate these relationships, results were compiled from studies that used regression analysis to these linkages in patients with CF.
Keywords: intermediate | outcome | end point | health outcome | mortality | health related quality of life | HRQoL | QoL | quality of life | cystic fibrosis | CF | rhGH | recombinant human growth hormone | human growth hormone | HGH
- Phung OJ, Coleman CI, Baker EL, et al. Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis. AHRQ Comparative Effectiveness Review No. 23 (Prepared by University of Connecticut-Hartford Hospital Evidence-based Practice Center under Contract No. 290-2007-10067-I). Rockville, MD: Agency for Healthcare Research and Quality; October 2010. AHRQ Publication No. 11-EHC003-EF.
Your slide tray is being processed.